There are 2789 resources available
1745P - Prediction of BSRTC class of repeated FNA based on molecular testing result upon the first FNA
Presenter: Yuntao Song
Session: ePoster Display
602P - Prevalence of castration-resistant prostate cancer (CRPC) of unknown metastatic status in the real-world setting: The AfrODiTA study
Presenter: Miguel Rodrigo-Aliaga
Session: ePoster Display
603P - Objective computerized cognitive assessment in men with metastatic castrate-resistant prostate cancer (mCRPC) randomly receiving darolutamide or enzalutamide in the ODENZA trial
Presenter: Emeline Colomba
Session: ePoster Display
604P - Predictive genomic biomarkers in non-metastatic castration resistant prostate cancer (nmCRPC) treated with androgen receptor pathway inhibitors (ARPi)
Presenter: Richard Gagnon
Session: ePoster Display
605P - Analysis of serial PET imaging and paired Tc99 scans in metastatic castration resistant prostate cancer (mCRPC) treated with enzalutamide
Presenter: Ravi Madan
Session: ePoster Display
606P - Role of serum biomarkers of bone metabolism in metastatic castration-resistance prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra223): PRORADIUM study final results
Presenter: Nuria Romero Laorden
Session: ePoster Display
607P - Impact of docetaxel on quality of life (QoL) in elderly and non-elderly metastatic castration-resistant prostate cancer (mCRPC) patients (Pts)
Presenter: Silvia Rubio-Novella
Session: ePoster Display
608P - Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC)
Presenter: Byung Ha Chung
Session: ePoster Display
609P - Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019
Presenter: Stephen Freedland
Session: ePoster Display